Randomized , double-blind , placebo-controlled , dose-ranging ( 1 , 2 , 4 , 8 mg b.d. alosetron ) , 12-week trial in 370 patients with diarrhoea-predominant or alternating constipation and diarrhoea irritable bowel syndrome .
